CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The RESYNC project aims to enhance cancer immunotherapy by reprogramming cancer cells into antigen-presenting cells using small molecules. This innovative approach seeks to improve immune responses against tumors while ensuring safe and efficient delivery through nanoparticle formulations.
THE
CHALLENGE:
Immunotherapy has revolutionized cancer treatment but most patients do not respond due to immune evasion mechanisms, including heterogeneity and lack of tumor antigen presentation.
Moreover, these therapies have met limited success in the treatment of solid tumors and are frequently associated with severe adverse effects.RADICAL
VISION:
The radical vision of the RESYNC consortium is to revolutionize cancer immunotherapy through small-molecule (SM)-based reprogramming of cancer cel…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, Lund
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Italy, Torino
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Romania, Cluj Napoca
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
